THOMAS MONATH to Yellow Fever Vaccine
This is a "connection" page, showing publications THOMAS MONATH has written about Yellow Fever Vaccine.
Connection Strength
8.093
-
Yellow fever vaccine supply: a possible solution. Lancet. 2016 Apr 16; 387(10028):1599-600.
Score: 0.506
-
Yellow fever. J Clin Virol. 2015 Mar; 64:160-73.
Score: 0.457
-
17D Yellow Fever Virus Vaccine. Am J Trop Med Hyg. 2013 Dec; 89(6):1225.
Score: 0.429
-
Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines. 2012 Apr; 11(4):427-48.
Score: 0.382
-
Yellow fever vaccine seroconversion in travelers. Am J Trop Med Hyg. 2011 Oct; 85(4):748-9.
Score: 0.369
-
Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine. 2011 Aug 11; 29(35):6008-16.
Score: 0.363
-
An inactivated cell-culture vaccine against yellow fever. N Engl J Med. 2011 Apr 07; 364(14):1326-33.
Score: 0.357
-
Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States. Am J Trop Med Hyg. 2010 May; 82(5):919-21.
Score: 0.335
-
Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine. 2010 May 14; 28(22):3827-40.
Score: 0.332
-
Dengue and yellow fever--challenges for the development and use of vaccines. N Engl J Med. 2007 Nov 29; 357(22):2222-5.
Score: 0.283
-
Yellow fever as an endemic/epidemic disease and priorities for vaccination. Bull Soc Pathol Exot. 2006 Dec; 99(5):341-7.
Score: 0.264
-
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin. 2006 Mar-Apr; 2(2):60-7.
Score: 0.251
-
New developments in flavivirus vaccines with special attention to yellow fever. Curr Opin Infect Dis. 2005 Oct; 18(5):387-94.
Score: 0.244
-
Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin. 2005 Sep-Oct; 1(5):207-14.
Score: 0.242
-
Yellow fever vaccine. Expert Rev Vaccines. 2005 Aug; 4(4):553-74.
Score: 0.241
-
Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg. 2005 Feb; 72(2):189-97.
Score: 0.233
-
Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017-2018 sylvatic outbreak in Brazil. Microbiol Spectr. 2024 May 02; 12(5):e0370323.
Score: 0.219
-
Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis. 2003 Oct 15; 188(8):1213-30.
Score: 0.212
-
Characterization and Investigation of Risk Factors for Late-Relapsing Hepatitis After Yellow Fever. Clin Infect Dis. 2023 08 22; 77(4):565-573.
Score: 0.210
-
Serum soluble mediators as prognostic biomarkers for morbidity, disease outcome, and late-relapsing hepatitis in yellow fever patients. Clin Immunol. 2023 06; 251:109321.
Score: 0.205
-
Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep. 2002 Nov 08; 51(RR-17):1-11; quiz CE1-4.
Score: 0.199
-
Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg. 2002 May; 66(5):533-41.
Score: 0.192
-
Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis. 2002 May 15; 34(10):1369-78.
Score: 0.192
-
Heterogeneous nature of the genome of the ARILVAX yellow fever 17D vaccine revealed by consensus sequencing. Vaccine. 2002 Jan 15; 20(7-8):996-9.
Score: 0.188
-
Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine. 2002 Jan 15; 20(7-8):1004-18.
Score: 0.188
-
Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial. Lancet. 2021 01 09; 397(10269):119-127.
Score: 0.176
-
Yellow Fever Remains a Potential Threat to Public Health. Vector Borne Zoonotic Dis. 2016 08; 16(8):566-7.
Score: 0.129
-
The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis. 2011 Aug; 11(8):622-32.
Score: 0.091
-
Viscerotropic disease following yellow fever vaccination in Peru. Vaccine. 2009 Oct 09; 27(43):5974-81.
Score: 0.080
-
Yellow fever recommendations for tourists to Kenya: a flawed risk assessment. J Travel Med. 2009 Mar-Apr; 16(2):146; author reply 146-7.
Score: 0.077
-
Yellow fever: 100 years of discovery. JAMA. 2008 Aug 27; 300(8):960-2.
Score: 0.074
-
17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005. Vaccine. 2007 Apr 12; 25(15):2758-65.
Score: 0.066
-
A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. J Virol. 2004 Sep; 78(18):9998-10008.
Score: 0.057
-
Pathogenesis and pathophysiology of yellow fever. Adv Virus Res. 2003; 60:343-95.
Score: 0.050
-
Prospects for development of a vaccine against the West Nile virus. Ann N Y Acad Sci. 2001 Dec; 951:1-12.
Score: 0.047
-
Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology. 2001 Nov 25; 290(2):309-19.
Score: 0.047
-
Yellow fever: an update. Lancet Infect Dis. 2001 Aug; 1(1):11-20.
Score: 0.046
-
Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. 2001 Jul 14; 358(9276):91-7.
Score: 0.045
-
Exercise-induced serum enzyme elevations confounding the evaluation of investigational drug toxicity. Report of two cases in a vaccine trial. Hum Vaccin. 2005 Jan-Feb; 1(1):24-9.
Score: 0.015